Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1702
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2637
    +0.0015 (+0.12%)
     
  • Bitcoin GBP

    55,716.65
    -414.81 (-0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Should Value Investors Consider Grifols (GRFS) Stock Right Now?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Grifols, S.A. GRFS stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Grifols has a trailing twelve months PE ratio of 19.68, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.37. If we focus on the stock’s long-term PE trend, the current level puts Grifols’ current PE ratio somewhat above its midpoint (which is 17.19) over the past three years.

Further, the stock’s PE also compares favorably with the Zacks classified Medical – Drugs industry’s trailing twelve months PE ratio, which stands at 41.11. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Grifols has a forward PE ratio (price relative to this year’s earnings) of just 18.46, so it is fair to say that a slightly more value-oriented path may be ahead for Grifols stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Grifols has a P/S ratio of about 3.10. This is marginally lower than the S&P 500 average, which comes in at 3.15 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.

If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Grifols currently has a Zacks Value Style Score of ‘B’, putting it into the top 40% of all stocks we cover from this look. This makes GRFS a solid choice for value investors.

What About the Stock Overall?

Though Grifols might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘C’ and a Momentum score of ‘C’. This gives GRFS a Zacks VGM score—or its overarching fundamental grade—of ‘B’. (You can read more about the Zacks Style Scores here >>)

ADVERTISEMENT

Meanwhile, the company’s recent earnings estimates have been encouraging. The full-year 2017 has seen one estimate go higher in the past thirty days, compared to none lower, while the full-year 2018 estimate has seen a similar trend in the same time period.

This has had a favorable impact on the consensus estimate, as the full-year 2017 consensus estimate has inched up by 0.9% in the past one month, while the full-year 2018 estimate has risen by about 0.8%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Grifols, S.A. Price and Consensus

 

Grifols, S.A. Price and Consensus | Grifols, S.A. Quote

Despite having a slightly bullish trend, GRFS carries a Zacks Rank #3 (Hold). This indicates that analysts have some apprehensions about the stock in the immediate future. Thus, we are looking for in-line performance from the company in the near term.

Bottom Line

Grifols is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 42% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the Zacks Medical - Drugs sector has clearly underperformed the broader market, as you can see below:

So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn favorable in this name first, but once that happen, this stock could be a compelling pick.

3 Top Picks to Ride the Hottest Tech Trend

Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...

Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Click for Free Grifols, S.A. (GRFS) Stock Analysis Report >>
 
To read this article on Zacks.com click here.
 
Zacks Investment Research